Welcome to our dedicated page for LMNX news (Ticker: LMNX), a resource for investors and traders seeking the latest updates and insights on LMNX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LMNX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LMNX's position in the market.
Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:30 p.m. Central Time. A live webcast of the presentation is accessible on their website and will be available for on-demand viewing within 24 hours for six months.
Luminex aims to empower labs with reliable and timely answers across various markets, including diagnostics and research.
Luminex Corporation (Nasdaq: LMNX) reported strong financial results for Q4 2020, achieving revenue of approximately $111M, a 23% increase from Q4 2019. Full-year revenue reached approximately $417M, up 25% year-over-year. Key highlights include MDx revenue growth to $228M and placing around 450 sample-to-answer systems. However, Luminex's Licensed Technologies Group revenue declined 2% to $147M, and Flow Cytometry revenue dropped 20% to $36M. They raised 2021 revenue guidance to approximately $480M, anticipating a 15% increase from 2020.
Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:30 p.m. Central Time. CEO Nachum Shamir and CFO Harriss Currie will lead the presentation, which will be available via live webcast on their website. An archive of the event will be accessible for six months after the conference. Luminex focuses on providing reliable laboratory solutions across various sectors, including diagnostics, research, and food safety.
Luminex Corporation (Nasdaq:LMNX) announced a $0.01 increase in its quarterly dividend, raising it to $0.10 per share of common stock. This dividend is payable on January 14, 2021, to stockholders of record as of December 23, 2020. This decision reflects the company's commitment to returning value to shareholders while maintaining a solid financial position.
Luminex Corporation (LMNX) reported a strong financial performance for Q3 2020, with total revenue of $106.1M, marking a 35% increase compared to Q3 2019. The gross margin improved to 60%, reflecting a 7 percentage point gain year-over-year. The company achieved net income of $1.8M or $0.04 per share, up 134% from last year. Key drivers included molecular diagnostics growth and BARDA funding for COVID-19-related products. Luminex forecasts revenues exceeding $475M in 2021, supported by product innovations and expansion.
Luminex Corporation (NASDAQ: LMNX) will report its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020. A press release will follow market close, and management will discuss highlights during a conference call at 5:00 p.m. ET on the same day. This conference call will be available via a live webcast on Luminex's website. The company aims to provide reliable and timely solutions across various markets, including clinical diagnostics and pharmaceutical research.
Luminex Corporation (Nasdaq: LMNX) reported approximately $106 million in revenues for Q3 2020, marking a 35% increase from Q3 2019. Key highlights include a nearly 100% rise in Molecular Diagnostics revenue to $60 million, while Licensed Technologies Group revenue fell 10% to $35 million. Flow Cytometry revenue increased 13% to $10 million. CEO Nachum Shamir noted strong demand for COVID-19-related products, with ongoing manufacturing expansions expected to ease supply constraints. The complete financial results will be discussed on November 2, 2020.
Luminex Corporation (NASDAQ: LMNX) has secured a $5,389,813 award from the Biomedical Advanced Research and Development Authority (BARDA) to support the development and 510(k) filing of its NxTAG Respiratory Pathogen Panel (RPP), which includes SARS-CoV-2 for COVID-19 testing. This initiative aims to address the urgent need for diagnostic tests that differentiate COVID-19 from other respiratory illnesses. The expanded panel will now feature 19 viral and 2 bacterial targets and can process up to 96 samples at once, returning results in about four hours.
Luminex Corporation (NASDAQ: LMNX) has received a $683,500 award from the Biomedical Advanced Research and Development Authority (BARDA) to enhance its xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. This assay detects antibodies for three viral antigens to evaluate previous SARS-CoV-2 infections and immune responses. With a specificity of 100% and sensitivity over 96%, Luminex plans to apply for Emergency Use Authorization upon project completion. This initiative supports communities in understanding immunity levels as they navigate COVID-19.
Luminex Corporation (Nasdaq:LMNX) declared a cash dividend of $0.09 per share for the third quarter of 2020. This dividend is payable on October 15, 2020, to stockholders of record as of the close of business on September 24, 2020. The company focuses on providing reliable solutions in clinical diagnostics, pharmaceutical discovery, and biomedical research, aiming to advance health through actionable insights.
